GlassScriptPhysician profile
John W Verheul
NPI 1356332290
$8,982.11
in general payments reported to CMS, 2019-2025
56 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $878 · 2021: $1,334 · 2022: $1,200 · 2023: $1,503 · 2024: $1,790 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.71 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $866.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $840.90 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $636.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $619.46 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $465.76 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.00 | 2019-2025 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $283.19 | 2024-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $281.63 | 2019-2020 | |
| Amarin Pharma, INC. | $257.26 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $181.58 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $164.85 | 2023-2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $164.60 | 2022-2025 | Auvelity, Symbravo |
| Avanir Pharmaceuticals, INC. | $161.90 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Verheul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.